Novel Biomarkers of Preeclampsia: Aquaporin, Fatty Acid, and S100B
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Preeclampsia
- Sponsor
- University of Alabama at Birmingham
- Enrollment
- 126
- Locations
- 1
- Primary Endpoint
- S100B protein fragments in maternal blood plasma
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This is a research study designed to help identify preeclampsia in pregnant women earlier, and possibly lead to better treatment for women preeclampsia.
Detailed Description
There is a paucity of biomarkers to predict preeclampsia and for predicting the severity of preeclampsia. This study was designed to identify novel biomarkers for both the prediction of preeclampsia in previously normal pregnancies and for the prediction of the severity of preeclampsia in preeclamptic women. The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence and the investigators also plan testing for novel markers using various approaches such as proteomics, lipidomics and genomics. The targeted markers will include Aquaporin 4 (AQP4), soluble aquaporin fragments, chemokines, and halogenated fatty acids in the plasma and/or spinal fluid. Aquaporin fragments and AQP4 have been hypothesized to correlate with severe headaches which are complications of severe preeclampsia. The investigators found in their murine studies that there is a correlation between the presence of halogenated fatty acids in the plasma and elevated blood pressure in a murine model of preeclampsia. The approaches will complement the targeted analyses to identify novel markers that have not been predicted yet.
Investigators
Tekuila Carter
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
Inclusion Criteria
- •Greater than or equal to 20 years of age
- •Greater than 24 weeks of gestation
- •Obstetrics/Anesthesia Team had decided that Combined Spinal/Epidural (CSE) or Spinal Anesthesia will be performed
Exclusion Criteria
- •Pre-pregnancy comorbidities:
- •hypertension, diabetes, or pulmonary hypertension
- •use of steroids, beta blockers, Ca channel antagonist, anticoagulants
- •cardiac or vascular conditions
- •severe headaches or visual disturbances
- •Inability to receive CSE or Spinal Anesthesia
- •Chorioamnionitis, fever, bronchitis, pneumonia
Outcomes
Primary Outcomes
S100B protein fragments in maternal blood plasma
Time Frame: Between hospital admission and prior to epidural or combined spinal/epidural anesthesia
The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence
Aquaporin 4 protein fragments in maternal blood plasma
Time Frame: Between hospital admission and prior to epidural or combined spinal/epidural anesthesia
The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence
Aquaporin 4 protein fragments in cerebrospinal fluid
Time Frame: At the time of spinal or combined spinal/epidural anesthesia
The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence
S100B protein fragments in cord blood and placental samples
Time Frame: Between delivery and 2 hours after delivery
The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence
S100B protein fragments in cerebrospinal fluid
Time Frame: At the time of spinal or combined spinal/epidural anesthesia
The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence
Aquaporin 4 protein fragments in cord blood and placental samples
Time Frame: Between delivery and 2 hours after delivery
The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence
Secondary Outcomes
- Fatty Acids in cerebrospinal fluid(during epidural or combined spinal/epidural anesthesia)
- Fatty acids in maternal blood(Between hospital admission and prior to epidural or combined spinal/epidural anesthesia)
- Fatty acids in cord blood and placental samples(Between immediately post-delivery and 2 hours after delivery)